Rezera Inc.

What the company does

Rezera is a clinical-stage biotechnology company developing internally invented, proprietary and wholly owned oral inhibitors of NLRP3. The company is focused on reducing inflammation driven by chronic NLRP3 activation and its associated inflammatory pathway. Its lead product candidate, ruvonoflast, is being developed for peripheral artery disease and, more broadly, atherosclerotic cardiovascular disease.

Use of proceeds

The company intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to advance ruvonoflast through topline data from its proposed Phase 3 clinical trial in peripheral artery disease and for general corporate purposes. If the net proceeds exceed the current estimate, the company expects to apply a portion of the additional proceeds to fund a trabzanoflast Phase 2 proof-of-concept trial.

Underwriters

Extracted from S-1/A 0001104659-26-124074, filed Nov 9, 2026 and verified against that filing text.

Key risk factors

• Uncertain use of proceeds

  “We may use the net proceeds for purposes that do not yield a significant return or any return at all for our stockholders.”

• Temporary investment losses

  “In addition, pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value.”

• Disclosure control limitations

  “Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.”

• Reduced reporting requirements

  “We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions.”